 |
0 Companies | 0 Products |
|
|
0 Products | |
0 Diseases | |
0 Trials |  |
0 News |  |
- | Journal: Transcriptomics in idiopathic pulmonary fibrosis unveiled: a new perspective from differentially expressed genes to therapeutic targets. (Pubmed Central) - Apr 7, 2024
Our findings provide new insights into the molecular basis of IPF and highlight the promise of therapeutic interventions. They emphasize the potential of targeting specific molecular pathways for the treatment of IPF, laying the foundation for further research and clinical work.
- | Journal: Zymogen Granule Protein 16-like and Carboxypeptidase B, new allergens in Hedgehog hypersensitivity. (Pubmed Central) - Aug 7, 2023
They emphasize the potential of targeting specific molecular pathways for the treatment of IPF, laying the foundation for further research and clinical work. No abstract available
- | Journal: Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals. (Pubmed Central) - May 26, 2023
Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering. Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
- Characterization of ZG16b protein exocrine function and biomarker potential for salivary gland damage in chronic graft vs. host disease (P1029) (Exhibit Hall; Poster Board No. P1029) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_1362;
In parallel, the utility of salivary ZG16b as a cGVHD and general salivary gland damage biomarker is being tested. This work will bring clarity Zg16b
- ulenistamab (PBP1510) / Prestige BioPharma
A clinical study assessing ZG16B/PAUF overexpression in high-grade ovarian serous adenocarcinoma () - Oct 23, 2022 - Abstract #ESGE2022ESGE_1005;
P1/2
Recently, a new anti-PAUF/ZG16B antibody, PBP1510, was developed by PrestigeBiopharma (NCT05141149). This study provides arguments in support of a future clinical trial to evaluate this antibody in patients with ovarian cancer.
- | Journal: A six-gene prognostic signature for both adult and pediatric acute myeloid leukemia identified with machine learning. (Pubmed Central) - Oct 18, 2022
When validated with two other independent cohorts, the 6-gene risk score models remain a significant predictor for OS. Investigating the common gene expression program is significant in that we may extrapolate the findings from adults to children and avoid unnecessary pediatric clinical trials.
- | Journal: Constructing a molecular subtype model of colon cancer using machine learning. (Pubmed Central) - Oct 4, 2022
Genomic analysis shows that there were no significant changes in differential genes. By constructing molecular subtypes of colon cancer, we discovered new colon cancer prognostic markers, which can provide direction for new treatments in the future.
- | Biomarker, Journal: Realistic biomarkers from plasma extracellular vesicles for detection of beryllium exposure. (Pubmed Central) - Sep 24, 2022
This is the first report of EV biomarkers associated with Be exposure and exposure levels. The biomarkers could be implemented in resource-limited settings for Be exposure assessment.
- | Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer. (Pubmed Central) - Jul 16, 2022
Importantly, ZG16 overexpression suppressed tumor growth in two syngeneic mouse models through blockage of PD-L1 expression in cancer cells meanwhile suppression of PD1 expression in T cells. We also showed that ZG16 could improve the effect of chemotherapy and may be delivered as a protein to serve as an immune checkpoint inhibitor to promote T-cell mediated immunity.
- | Journal, Cancer stem cells, Pan tumor: Pan-Cancer Single-Cell Analysis Reveals the Core Factors and Pathway in Specific Cancer Stem Cells of Upper Gastrointestinal Cancer. (Pubmed Central) - Jun 4, 2022
These findings establish the core signal pathway that connects poor eating habits and UGIC. Our system provides deeper insights into UGIC carcinogens and a platform to promote gastrointestinal cancer diagnosis and therapy.
- ulenistamab (PBP1510) / Prestige BioPharma
First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2183;
The efficacy and safety data presented here, along with the data from in vivo mouse studies demonstrating superior anti-tumour activity of PBP1510 treatment, support further clinical development of PBP1510 as a novel anti-cancer agent to treat PAUF-positive PC. The pivotal step of advancing PBP1510 into initial human studies is now in progress.
- | Biomarker, Journal: Identification of Novel Diagnostic Biomarkers in Prostate Adenocarcinoma Based on the Stromal-Immune Score and Analysis of the WGCNA and ceRNA Network. (Pubmed Central) - Mar 24, 2022
In this systematic study for ceRNA networks in the tumor environment, we screened out potential biomarkers to predict prognosis for prostate cancer. Our findings might apply a valuable tool to improve prostate cancer clinical management and the new target for mechanism study and therapy.
- | Journal: Pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor. (Pubmed Central) - Mar 1, 2022
Our data identified tumor-secreted circulating PAUF as a key factor of cachexia, causing muscle wasting in mice. Neutralizing PAUF may be a useful therapeutic strategy for the treatment of pancreatic cancer-induced cachexia.
- | Journal: Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease. (Pubmed Central) - Jan 11, 2022
Single-cell RNA-seq analysis of healthy MSG localized ZG16B expression to two discrete acinar cell populations. Reduced ZG16B expression may indicate specific cGVHD activity and possibly general salivary gland dysfunction.
- || Clinical, Observational data, Journal: Impact of the Glycemic Level on the Salivary Proteome of Middle-Aged and Elderly People With Type 2 Diabetes Mellitus: An Observational Study. (Pubmed Central) - Dec 28, 2021
In conclusion, poorly controlled hyperglycemia may affect salivary proteins through various pathways, including oxidative stress and glandular secretion. Furthermore, the differentially expressed proteins, especially the three proteins with the best differentiation, might serve as an anchor point for the further study of hyperglycemia and oral diseases.
- PBP1510 / Prestige BioPharma
Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb) ([VIRTUAL]) - Dec 6, 2021 - Abstract #ESMOTAT2022ESMO_TAT_67;
As a result, PBP1510 was granted Orphan Drug Designation by EMA, US FDA and Korea MFDS. The pivotal step of advancing PBP1510 into initial human studies is now in progress.
- | Journal: Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics. (Pubmed Central) - Sep 4, 2021
The pivotal step of advancing PBP1510 into initial human studies is now in progress. CYP26A1, FAM110C, SMYD3 and ZG16 are unique genes to differentiate HBV infection and HBV-related HCC, and expected to be novel targets for HBV-related HCC occurrence and prognostic judgement.
- | Journal: Bioinformatics analysis of structures and ligand-bindings of predicted zymogen granule protein observed on Bali cattle (Bos javanicus) saliva. (Pubmed Central) - Aug 17, 2021
The structure of P-G3MZ19 of Bali cattle saliva and its ligand-binding sites have been successfully determined by using bioinformatics techniques. The biological and immunological roles of the peptide are currently under investigation based on P-G3MZ19 synthetic peptides.
- | Biomarker, Journal: Identification of core biomarkers associated with pathogenesis and prognostic outcomes of laryngeal squamous-cell cancer using bioinformatics analysis. (Pubmed Central) - Apr 28, 2021
The biological and immunological roles of the peptide are currently under investigation based on P-G3MZ19 synthetic peptides. Our findings might shed some new light on the pathogenesis of LSCC and help identify new therapeutic targets of LSCC.
- | Biomarker, Journal: Identification of ZG16B as a prognostic biomarker in breast cancer. (Pubmed Central) - Dec 19, 2020
In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.
- | Journal: PAUF/ZG16B promotes colorectal cancer progression through alterations of the mitotic functions and the Wnt/β-catenin pathway. (Pubmed Central) - Sep 2, 2020
Altogether, our results suggest that PAUF depletion increases aneuploidy, promotes apoptosis and activates the Wnt/β-catenin pathway in colorectal cancer cells facilitating cancer progression. In summary, PAUF behaves as a multifunctional protein, with different roles in cancer progression according to the extra- or intracellular expression, suggesting a therapeutic value for colorectal cancer.
- Xtandi (enzalutamide) / Pfizer, Astellas
[VIRTUAL] Molecular reprogramming and rewiring of prostate cancer cells after enzalutamide exposure (WEWCC: 146C) - May 17, 2020 - Abstract #AUA2020AUA_2084;
Our findings emphasized the role of molecular reprogramming and gene rewiring leading to the development of enzalutamide resistance. Source of Funding: VA Merit Review 1I01BX002494; Department of Defense grant W81XWH-15-1-0558, W81XWH-18-1-0618 and W81XWH-19-1-0720 to SG.
- Xtandi (enzalutamide) / Pfizer, Astellas
Metabolic reprogramming fuels prostate cancer cells towards enzalutamide resistance (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3403;
Taken together, our findings demonstrate molecular alterations after enzalutamide exposure may provide fuel to the cells through metabolic reprogramming. Clinically, targeting the aforementioned genes associated with metabolic reprogramming may lead to control of the enzalutamide-mediated recurrence of prostate cancer.
- [VIRTUAL] RELAPSE, RECURRENCE AND CHEMORESISTANCE IN OVARIAN CANCER- A TARGETED LITERATURE REVIEW () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_532;
The literature underscores that chemoresistance plays a role in the high relapse and recurrence rates that follow surgery and chemotherapy. Further research is necessary to treat chemoresistance and thus decrease relapses and recurrences in OC.
- | Journal, IO Biomarker: Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. (Pubmed Central) - Nov 30, 2019
Multivariate analysis indicated that PAUF, TLR4, and PAUF/TLR4 expression are independent prognostic factor for progression-free survival, while TLR4 and PAUF/TLR4 expression were independent prognostic factors for overall survival. Our results suggest that PAUF has a role in ovarian cancer progression and is a potential prognostic marker and novel chemotherapeutic target for ovarian cancer.
- | Biomarker, Clinical, Review, Journal: Molecular profiling of mucinous epithelial ovarian cancer by weighted gene co-expression network analysis. (Pubmed Central) - Jul 19, 2019
Our work proposed an applicable framework of molecular characteristics for patients with mEOC, which may help us to obtain a precise and comprehensive understanding on the molecular complexities of mEOC. The hub genes identified in our study, as potential specific biomarkers of mEOC, may be applied in the early diagnosis of mEOC in the future.